Theranostics 2021; 11(20):9833-9846. doi:10.7150/thno.62449 This issue Cite

Research Paper

A programmable hierarchical-responsive nanoCRISPR elicits robust activation of endogenous target to treat cancer

Chao Liu#, Ning Wang#, Rui Luo, Lu Li, Wen Yang, Xiye Wang, Meiling Shen, Qinjie Wu, Changyang Gong

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital Sichuan University, Chengdu, 610041, P. R. China.
#These authors contributed equally to this work.

Citation:
Liu C, Wang N, Luo R, Li L, Yang W, Wang X, Shen M, Wu Q, Gong C. A programmable hierarchical-responsive nanoCRISPR elicits robust activation of endogenous target to treat cancer. Theranostics 2021; 11(20):9833-9846. doi:10.7150/thno.62449. https://www.thno.org/v11p9833.htm
Other styles

File import instruction

Abstract

Graphic abstract

Despite promising progress of cancer gene therapy made, these therapeutics were still limited by the diversity of gene sizes and types. CRISPR/dCas9 mediated activation of tumor endogenous gene has shown great potential to surmount hinders of genetic varieties during the process of cancer gene therapy. However, the blood interference along with complicated tumor extra/intracellular microenvironment substantially compromise the performance of CRISPR/dCas9-based therapeutics in vivo.

Methods: In this study, we constructed a programmable hierarchical-responsive nanoCRISPR (PICASSO) that can achieve sequential responses to the multiple physiological barriers in vivo. The core-shell structure endows PICASSO with long blood circulation capacity and tumor target accumulation as well as efficient cellular uptake and lysosomal escape, leading to high-performance of CRISPR/dCas9-mediated gene activation, which favors the antitumor efficacy.

Results: Owing to these properties, PICASSO facilitated CRISPR/dCas9 mediated efficient transcriptional activation of various types of endogenous gene, and long non-protein-coding genes (LncRNA) containing targets ranging in size from ~1 kb to ~2000 kb in tumor cells. Intravenous administration of PICASSO to the tumor-bearing mice can achieve effective transcriptional activation of therapeutic endogenous gene, resulting in remarkable CRISPR/dCas9-mediate tumor inhibition with minimal adverse effect.

Conclusions: Taken together, these characteristics allow PICASSO to unleash the potential of CRISPR/dCas9-based therapeutics in oncological treatment. The study provides a simple and versatile strategy to break through the restriction of sizes and types against cancer by utilization of tumor endogenous gene.

Keywords: programmable hierarchical-responsive, CRISPR/dCas9, transcriptional activation, cancer therapy, gene delivery


Citation styles

APA
Liu, C., Wang, N., Luo, R., Li, L., Yang, W., Wang, X., Shen, M., Wu, Q., Gong, C. (2021). A programmable hierarchical-responsive nanoCRISPR elicits robust activation of endogenous target to treat cancer. Theranostics, 11(20), 9833-9846. https://doi.org/10.7150/thno.62449.

ACS
Liu, C.; Wang, N.; Luo, R.; Li, L.; Yang, W.; Wang, X.; Shen, M.; Wu, Q.; Gong, C. A programmable hierarchical-responsive nanoCRISPR elicits robust activation of endogenous target to treat cancer. Theranostics 2021, 11 (20), 9833-9846. DOI: 10.7150/thno.62449.

NLM
Liu C, Wang N, Luo R, Li L, Yang W, Wang X, Shen M, Wu Q, Gong C. A programmable hierarchical-responsive nanoCRISPR elicits robust activation of endogenous target to treat cancer. Theranostics 2021; 11(20):9833-9846. doi:10.7150/thno.62449. https://www.thno.org/v11p9833.htm

CSE
Liu C, Wang N, Luo R, Li L, Yang W, Wang X, Shen M, Wu Q, Gong C. 2021. A programmable hierarchical-responsive nanoCRISPR elicits robust activation of endogenous target to treat cancer. Theranostics. 11(20):9833-9846.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.